Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment
Abstract Aims This study assessed the relationship between highly active antiretroviral therapy (HAART) duration and cardiometabolic disorders in HIV-infected Cameroonians. Methods HIV-infected Cameroonians aged 21 years or above were cross-sectionally recruited at the Yaoundé Central Hospital, a ce...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolism 2013-02, Vol.39 (1), p.71-77 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 71 |
| container_title | Diabetes & metabolism |
| container_volume | 39 |
| creator | Ekali, L.G Johnstone, L.K Echouffo-Tcheugui, J.B Kouanfack, C Dehayem, M.Y Fezeu, L Nouthe, B Hayes, L Unwin, N.C Sobngwi, E |
| description | Abstract Aims This study assessed the relationship between highly active antiretroviral therapy (HAART) duration and cardiometabolic disorders in HIV-infected Cameroonians. Methods HIV-infected Cameroonians aged 21 years or above were cross-sectionally recruited at the Yaoundé Central Hospital, a certified HIV care centre, and their anthropometry, body composition (impedancemetry), fasting blood glucose (FBG) and lipid levels, and insulin sensitivity (IS; short insulin tolerance test) were measured. Results A total of 143 participants with various durations of HAART [treatment-naïve ( n = 28), 1–13 months ( n = 44), 14–33 months ( n = 35) and 34–86 months ( n = 36)] were recruited. They were mostly women (72%), and had a mean age of 39.5 (SD: 9.8) years. Half (52%) were using a stavudine-containing regimen. There was a significant trend towards a positive change in body mass index and waist-to-hip ratio with increasing duration of HAART (all P = 0.02). Systolic ( P = 0.04) and diastolic ( P = 0.03) blood pressure, total cholesterol ( P = 0.01), prevalence of hypertension ( P = 0.04) and hypercholesterolaemia ( P = 0.007) were also significantly increased with HAART duration, whereas triglycerides, FBG and IS were unaffected. Clustering of metabolic disorders increased ( P = 0.02 for ≥ 1 component of the metabolic syndrome and P = 0.09 for ≥ 2 components) with HAART duration. Conclusion HAART duration is associated with obesity, fat distribution, blood pressure and cholesterol levels in HIV-infected Cameroonians, but does not appear to significantly affect glucose metabolism. |
| doi_str_mv | 10.1016/j.diabet.2012.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02644210v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1262363612001590</els_id><sourcerecordid>1312842802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-18427d12781c96782ed89b913ba303d29d7045e9e7183e678bb377354fa9098c3</originalsourceid><addsrcrecordid>eNqFktuKFDEQhhtR3IO-gUhuBL3oMYc-pG-EYXB3hAFB1-uQTqrXjD3JmqQH5h18aKvpcQVvvKoQvv-vov4qileMrhhlzfv9yjrdQ15xyviKyhWWJ8Ulk60sWSvpU3zzhpeiEc1FcZXSniLRCfm8uOCC1aIS9WXx60an7Pw96ccQLLkfJxMSEO0tcT5No_MkgU8uu6PLJ6IjkMnrYQCTwZL-RLbr9Zc7YqeoswseRWSjDxBD8E77RCIYQCk2GFxMuUTD2T27CDmGo4t6JDmCzgfw-UXxbNBjgpfnel18u_l4t9mWu8-3nzbrXWkqyXLJZMVby3grmemaVnKwsus7JnotqLC8sy2tauigZVIAAn0v2lbU1aA72kkjrot3i-93PaqH6A46nlTQTm3XOzX_Ud5UFWf0yJB9u7APMfycIGV1cMnAOGoPYUqKCcZxHkk5otWCmhhSijA8ejOq5szUXi2ZqTkzRaXCgrLX5w5TfwD7KPoTEgJvzoBORo9D1N649Jdrad1xOnMfFg5wd0cHUSXjwBuwuG2TlQ3uf5P8a2AwL4c9f8AJ0j5M0WMuiqmEGvV1vq_5vBjH06o7Kn4DhKjL2A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1312842802</pqid></control><display><type>article</type><title>Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ekali, L.G ; Johnstone, L.K ; Echouffo-Tcheugui, J.B ; Kouanfack, C ; Dehayem, M.Y ; Fezeu, L ; Nouthe, B ; Hayes, L ; Unwin, N.C ; Sobngwi, E</creator><creatorcontrib>Ekali, L.G ; Johnstone, L.K ; Echouffo-Tcheugui, J.B ; Kouanfack, C ; Dehayem, M.Y ; Fezeu, L ; Nouthe, B ; Hayes, L ; Unwin, N.C ; Sobngwi, E</creatorcontrib><description>Abstract Aims This study assessed the relationship between highly active antiretroviral therapy (HAART) duration and cardiometabolic disorders in HIV-infected Cameroonians. Methods HIV-infected Cameroonians aged 21 years or above were cross-sectionally recruited at the Yaoundé Central Hospital, a certified HIV care centre, and their anthropometry, body composition (impedancemetry), fasting blood glucose (FBG) and lipid levels, and insulin sensitivity (IS; short insulin tolerance test) were measured. Results A total of 143 participants with various durations of HAART [treatment-naïve ( n = 28), 1–13 months ( n = 44), 14–33 months ( n = 35) and 34–86 months ( n = 36)] were recruited. They were mostly women (72%), and had a mean age of 39.5 (SD: 9.8) years. Half (52%) were using a stavudine-containing regimen. There was a significant trend towards a positive change in body mass index and waist-to-hip ratio with increasing duration of HAART (all P = 0.02). Systolic ( P = 0.04) and diastolic ( P = 0.03) blood pressure, total cholesterol ( P = 0.01), prevalence of hypertension ( P = 0.04) and hypercholesterolaemia ( P = 0.007) were also significantly increased with HAART duration, whereas triglycerides, FBG and IS were unaffected. Clustering of metabolic disorders increased ( P = 0.02 for ≥ 1 component of the metabolic syndrome and P = 0.09 for ≥ 2 components) with HAART duration. Conclusion HAART duration is associated with obesity, fat distribution, blood pressure and cholesterol levels in HIV-infected Cameroonians, but does not appear to significantly affect glucose metabolism.</description><identifier>ISSN: 1262-3636</identifier><identifier>EISSN: 1878-1780</identifier><identifier>DOI: 10.1016/j.diabet.2012.08.012</identifier><identifier>PMID: 23153435</identifier><language>eng</language><publisher>Paris: Elsevier Masson SAS</publisher><subject>Anti-HIV Agents - therapeutic use ; Antiretroviral therapy ; Antiretroviral Therapy, Highly Active ; Antirétroviraux ; Biological and medical sciences ; Blood Glucose - metabolism ; Blood Pressure ; Body Fat Distribution ; Cameroon ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - drug therapy ; Cardiovascular risk factors ; Cross-Sectional Studies ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinology & Metabolism ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Facteurs de risque cardiovasculaires ; Fasting ; Female ; Health Services Accessibility ; HIV Infections - drug therapy ; HIV Infections - metabolism ; Human immunodeficiency virus ; Humans ; Hyperglycaemia ; Hyperglycémie ; Insulin Resistance ; Insulin sensitivity ; Internal Medicine ; Life Sciences ; Lipids - blood ; Male ; Medical sciences ; Sensibilité à l’insuline ; Stavudine - therapeutic use ; Time Factors ; Virus de l’immunodéficience humaine</subject><ispartof>Diabetes & metabolism, 2013-02, Vol.39 (1), p.71-77</ispartof><rights>2012</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2012. Published by Elsevier Masson SAS.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-18427d12781c96782ed89b913ba303d29d7045e9e7183e678bb377354fa9098c3</citedby><cites>FETCH-LOGICAL-c481t-18427d12781c96782ed89b913ba303d29d7045e9e7183e678bb377354fa9098c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1262363612001590$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27059205$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23153435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.inrae.fr/hal-02644210$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ekali, L.G</creatorcontrib><creatorcontrib>Johnstone, L.K</creatorcontrib><creatorcontrib>Echouffo-Tcheugui, J.B</creatorcontrib><creatorcontrib>Kouanfack, C</creatorcontrib><creatorcontrib>Dehayem, M.Y</creatorcontrib><creatorcontrib>Fezeu, L</creatorcontrib><creatorcontrib>Nouthe, B</creatorcontrib><creatorcontrib>Hayes, L</creatorcontrib><creatorcontrib>Unwin, N.C</creatorcontrib><creatorcontrib>Sobngwi, E</creatorcontrib><title>Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment</title><title>Diabetes & metabolism</title><addtitle>Diabetes Metab</addtitle><description>Abstract Aims This study assessed the relationship between highly active antiretroviral therapy (HAART) duration and cardiometabolic disorders in HIV-infected Cameroonians. Methods HIV-infected Cameroonians aged 21 years or above were cross-sectionally recruited at the Yaoundé Central Hospital, a certified HIV care centre, and their anthropometry, body composition (impedancemetry), fasting blood glucose (FBG) and lipid levels, and insulin sensitivity (IS; short insulin tolerance test) were measured. Results A total of 143 participants with various durations of HAART [treatment-naïve ( n = 28), 1–13 months ( n = 44), 14–33 months ( n = 35) and 34–86 months ( n = 36)] were recruited. They were mostly women (72%), and had a mean age of 39.5 (SD: 9.8) years. Half (52%) were using a stavudine-containing regimen. There was a significant trend towards a positive change in body mass index and waist-to-hip ratio with increasing duration of HAART (all P = 0.02). Systolic ( P = 0.04) and diastolic ( P = 0.03) blood pressure, total cholesterol ( P = 0.01), prevalence of hypertension ( P = 0.04) and hypercholesterolaemia ( P = 0.007) were also significantly increased with HAART duration, whereas triglycerides, FBG and IS were unaffected. Clustering of metabolic disorders increased ( P = 0.02 for ≥ 1 component of the metabolic syndrome and P = 0.09 for ≥ 2 components) with HAART duration. Conclusion HAART duration is associated with obesity, fat distribution, blood pressure and cholesterol levels in HIV-infected Cameroonians, but does not appear to significantly affect glucose metabolism.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral therapy</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antirétroviraux</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Blood Pressure</subject><subject>Body Fat Distribution</subject><subject>Cameroon</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular risk factors</subject><subject>Cross-Sectional Studies</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinology & Metabolism</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Facteurs de risque cardiovasculaires</subject><subject>Fasting</subject><subject>Female</subject><subject>Health Services Accessibility</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - metabolism</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hyperglycaemia</subject><subject>Hyperglycémie</subject><subject>Insulin Resistance</subject><subject>Insulin sensitivity</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Sensibilité à l’insuline</subject><subject>Stavudine - therapeutic use</subject><subject>Time Factors</subject><subject>Virus de l’immunodéficience humaine</subject><issn>1262-3636</issn><issn>1878-1780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFktuKFDEQhhtR3IO-gUhuBL3oMYc-pG-EYXB3hAFB1-uQTqrXjD3JmqQH5h18aKvpcQVvvKoQvv-vov4qileMrhhlzfv9yjrdQ15xyviKyhWWJ8Ulk60sWSvpU3zzhpeiEc1FcZXSniLRCfm8uOCC1aIS9WXx60an7Pw96ccQLLkfJxMSEO0tcT5No_MkgU8uu6PLJ6IjkMnrYQCTwZL-RLbr9Zc7YqeoswseRWSjDxBD8E77RCIYQCk2GFxMuUTD2T27CDmGo4t6JDmCzgfw-UXxbNBjgpfnel18u_l4t9mWu8-3nzbrXWkqyXLJZMVby3grmemaVnKwsus7JnotqLC8sy2tauigZVIAAn0v2lbU1aA72kkjrot3i-93PaqH6A46nlTQTm3XOzX_Ud5UFWf0yJB9u7APMfycIGV1cMnAOGoPYUqKCcZxHkk5otWCmhhSijA8ejOq5szUXi2ZqTkzRaXCgrLX5w5TfwD7KPoTEgJvzoBORo9D1N649Jdrad1xOnMfFg5wd0cHUSXjwBuwuG2TlQ3uf5P8a2AwL4c9f8AJ0j5M0WMuiqmEGvV1vq_5vBjH06o7Kn4DhKjL2A</recordid><startdate>20130201</startdate><enddate>20130201</enddate><creator>Ekali, L.G</creator><creator>Johnstone, L.K</creator><creator>Echouffo-Tcheugui, J.B</creator><creator>Kouanfack, C</creator><creator>Dehayem, M.Y</creator><creator>Fezeu, L</creator><creator>Nouthe, B</creator><creator>Hayes, L</creator><creator>Unwin, N.C</creator><creator>Sobngwi, E</creator><general>Elsevier Masson SAS</general><general>Masson</general><general>Elsevier Masson</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20130201</creationdate><title>Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment</title><author>Ekali, L.G ; Johnstone, L.K ; Echouffo-Tcheugui, J.B ; Kouanfack, C ; Dehayem, M.Y ; Fezeu, L ; Nouthe, B ; Hayes, L ; Unwin, N.C ; Sobngwi, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-18427d12781c96782ed89b913ba303d29d7045e9e7183e678bb377354fa9098c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral therapy</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antirétroviraux</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Blood Pressure</topic><topic>Body Fat Distribution</topic><topic>Cameroon</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular risk factors</topic><topic>Cross-Sectional Studies</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinology & Metabolism</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Facteurs de risque cardiovasculaires</topic><topic>Fasting</topic><topic>Female</topic><topic>Health Services Accessibility</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - metabolism</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hyperglycaemia</topic><topic>Hyperglycémie</topic><topic>Insulin Resistance</topic><topic>Insulin sensitivity</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Sensibilité à l’insuline</topic><topic>Stavudine - therapeutic use</topic><topic>Time Factors</topic><topic>Virus de l’immunodéficience humaine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ekali, L.G</creatorcontrib><creatorcontrib>Johnstone, L.K</creatorcontrib><creatorcontrib>Echouffo-Tcheugui, J.B</creatorcontrib><creatorcontrib>Kouanfack, C</creatorcontrib><creatorcontrib>Dehayem, M.Y</creatorcontrib><creatorcontrib>Fezeu, L</creatorcontrib><creatorcontrib>Nouthe, B</creatorcontrib><creatorcontrib>Hayes, L</creatorcontrib><creatorcontrib>Unwin, N.C</creatorcontrib><creatorcontrib>Sobngwi, E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Diabetes & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ekali, L.G</au><au>Johnstone, L.K</au><au>Echouffo-Tcheugui, J.B</au><au>Kouanfack, C</au><au>Dehayem, M.Y</au><au>Fezeu, L</au><au>Nouthe, B</au><au>Hayes, L</au><au>Unwin, N.C</au><au>Sobngwi, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment</atitle><jtitle>Diabetes & metabolism</jtitle><addtitle>Diabetes Metab</addtitle><date>2013-02-01</date><risdate>2013</risdate><volume>39</volume><issue>1</issue><spage>71</spage><epage>77</epage><pages>71-77</pages><issn>1262-3636</issn><eissn>1878-1780</eissn><abstract>Abstract Aims This study assessed the relationship between highly active antiretroviral therapy (HAART) duration and cardiometabolic disorders in HIV-infected Cameroonians. Methods HIV-infected Cameroonians aged 21 years or above were cross-sectionally recruited at the Yaoundé Central Hospital, a certified HIV care centre, and their anthropometry, body composition (impedancemetry), fasting blood glucose (FBG) and lipid levels, and insulin sensitivity (IS; short insulin tolerance test) were measured. Results A total of 143 participants with various durations of HAART [treatment-naïve ( n = 28), 1–13 months ( n = 44), 14–33 months ( n = 35) and 34–86 months ( n = 36)] were recruited. They were mostly women (72%), and had a mean age of 39.5 (SD: 9.8) years. Half (52%) were using a stavudine-containing regimen. There was a significant trend towards a positive change in body mass index and waist-to-hip ratio with increasing duration of HAART (all P = 0.02). Systolic ( P = 0.04) and diastolic ( P = 0.03) blood pressure, total cholesterol ( P = 0.01), prevalence of hypertension ( P = 0.04) and hypercholesterolaemia ( P = 0.007) were also significantly increased with HAART duration, whereas triglycerides, FBG and IS were unaffected. Clustering of metabolic disorders increased ( P = 0.02 for ≥ 1 component of the metabolic syndrome and P = 0.09 for ≥ 2 components) with HAART duration. Conclusion HAART duration is associated with obesity, fat distribution, blood pressure and cholesterol levels in HIV-infected Cameroonians, but does not appear to significantly affect glucose metabolism.</abstract><cop>Paris</cop><pub>Elsevier Masson SAS</pub><pmid>23153435</pmid><doi>10.1016/j.diabet.2012.08.012</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1262-3636 |
| ispartof | Diabetes & metabolism, 2013-02, Vol.39 (1), p.71-77 |
| issn | 1262-3636 1878-1780 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02644210v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-HIV Agents - therapeutic use Antiretroviral therapy Antiretroviral Therapy, Highly Active Antirétroviraux Biological and medical sciences Blood Glucose - metabolism Blood Pressure Body Fat Distribution Cameroon Cardiovascular Diseases - blood Cardiovascular Diseases - drug therapy Cardiovascular risk factors Cross-Sectional Studies Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinology & Metabolism Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Facteurs de risque cardiovasculaires Fasting Female Health Services Accessibility HIV Infections - drug therapy HIV Infections - metabolism Human immunodeficiency virus Humans Hyperglycaemia Hyperglycémie Insulin Resistance Insulin sensitivity Internal Medicine Life Sciences Lipids - blood Male Medical sciences Sensibilité à l’insuline Stavudine - therapeutic use Time Factors Virus de l’immunodéficience humaine |
| title | Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A22%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fasting%20blood%20glucose%20and%20insulin%20sensitivity%20are%20unaffected%20by%20HAART%20duration%20in%20Cameroonians%20receiving%20first-line%20antiretroviral%20treatment&rft.jtitle=Diabetes%20&%20metabolism&rft.au=Ekali,%20L.G&rft.date=2013-02-01&rft.volume=39&rft.issue=1&rft.spage=71&rft.epage=77&rft.pages=71-77&rft.issn=1262-3636&rft.eissn=1878-1780&rft_id=info:doi/10.1016/j.diabet.2012.08.012&rft_dat=%3Cproquest_hal_p%3E1312842802%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1312842802&rft_id=info:pmid/23153435&rft_els_id=S1262363612001590&rfr_iscdi=true |